Glaukos (NYSE:GKOS) is an ophthalmic medical technology and pharmaceutical company committed to developing and commercializing breakthrough products and procedures designed to transform the treatment of eye diseases. The company's portfolio primarily focuses on advanced solutions for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos is dedicated to leveraging its robust R&D capabilities to enhance and expand its product offerings, with the objective of improving clinical outcomes for patients suffering from eye diseases. Its innovative projects and products aim to provide long-term, sustainable value to patients, healthcare providers, and stakeholders alike.